Delivery Order SPE2DR25D1109-SPE2DR26FFJ9S
Award Date 1/2/26
Potential Completion Date 1/26/26
Potential Value $13K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $7,277.44 for NOVOSEVEN RT 5 mg vials on September 18, 2025, with an ultimate completion date of October 9, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $15,208.90 to AmerisourceBergen Drug Corp for NOVOSEVEN RT 2 MG vials, with completion scheduled for December 1, 2025. This firm fixed-price delivery order was awarded on November 6, 2025, without set-aside designation, utilizing open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's substantial...
- The Defense Logistics Agency awarded a delivery order valued at $7,277.44 to AmerisourceBergen Drug Corp for NOVOSEVEN RT 5 mg vials, with completion required by May 30, 2025. This non-set-aside, firm fixed-price contract was awarded competitively on May 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. NOVOSEVEN RT is a recombinant activated Factor VII used in treating bleeding disorders, representing a specialized pharmaceutical product...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $12,167.12 for NOVOSEVEN RT 2 mg vials, a pharmaceutical product used primarily for hemophilia treatment and bleeding disorder management. The award was issued by the Defense Logistics Agency on November 10, 2025, with an ultimate completion date of December 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitively-procured delivery order valued at approximately $51K for NOVOSEVEN RT 5 mg vials. The contract, issued by the Defense Logistics Agency under its Defense Supply Chain operations, carries a firm fixed price structure and is scheduled for completion by September 12, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency has awarded a delivery order valued at $5,772.72 to AmerisourceBergen Drug Corp for the supply of Novoseven RT 2 mg vials. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply agreement extending through December 2026. The delivery order is scheduled for completion by August 15, 2025, with fulfillment...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of NOVOSEVEN RT 5 MG VIALS, a medication, with a ceiling value of $7,277.44 and a period of performance through June 18, 2025. The award is not set aside and is a firm fixed-price delivery order contract. Amerisourcebergen Drug Corp is the prime contractor and will be...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,846.64 firm fixed-price delivery order is for the supply of NovoSeven RT 2 mg vials, a specialty medication. This award is a part of AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and...
- This federal contract award is for the delivery of NovoSeven RT 5 mg vials to the Defense Logistics Agency (DLA). The $80,051.84 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on March 14, 2025, with a completion date of April 4, 2025. This award is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The $82,935.48 firm-fixed-price contract is for the supply of NovoSeven RT 5 mg vials, a pharmaceutical product. The contract has an ultimate completion date of August 5, 2024. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle...